FUTU staged a sharp 20% rebound on May 26, but the recovery lands inside one of the most dramatic positioning shifts the stock has seen all year — and the data suggests the market is far from convinced the worst is over.
The most telling development this week is not the bounce. It is what shorts did into it. Short interest jumped 44% in a single session to 3.5% of the free float — the highest reading in the 30-day history and a clean break above the 2.5% level that had held steady for most of the prior six weeks. That move came the day after the stock was already down 28% on the CSRC fine announcement, meaning fresh bears pressed their position into the carnage rather than covered into it. The ORTEX short score surged from 41-42 (where it had sat for weeks) to 59.8 on May 26 — the highest in the observed history and a move that reflects the combined weight of rising short interest, tightening availability, and climbing borrow costs all arriving together.
Borrow conditions tightened dramatically to match. Availability collapsed from a loose 642% on May 22 to 120% on May 26 — still technically above the tight threshold, but a drop of 86% in four days and a reading that marks a new 52-week low. Cost to borrow climbed to 0.57%, up 41% on the week, though still cheap in absolute terms. The picture is one of a lending market that went from essentially unrestricted to meaningfully constrained in under a week. Options positioning flipped in the opposite direction: the put/call ratio dropped sharply to 1.63 from the 52-week high of 3.64 hit just four days earlier on May 22. A PCR running more than a standard deviation below its 20-day average suggests traders who had loaded up on puts ahead of earnings were taking profits — or closing hedges — into the rally, not adding new protection. The dual signal — short interest rising, PCR falling — implies the dominant trade on the day was fresh outright shorts rather than put buying.
The Street's view on valuation shifted fast and hard. JP Morgan's Katherine Lei cut her rating from Overweight to Neutral on May 22 and slashed her target from $300 to $87 — a cut of more than 70% in a single move, reflecting the regulatory risk the market had not previously priced. She then raised it modestly to $100 on May 26, consistent with writing the stock back up to near current levels after the bounce. Barclays remains Overweight with a $200 target, but that figure is now almost double the current price — a gap that will require material regulatory resolution to close. The mean analyst price target in the data ($1,526) looks mismatched with the ADR price and is likely an artefact of a different listing or stale data; readers should rely on the individual firm targets cited here rather than the aggregate. On valuation, the P/E contracted to 8.5x from 12.6x thirty days ago — a compression of roughly a third, driven almost entirely by the price collapse. Price-to-book has halved over the same period. At these multiples Futu screens as cheap, but cheap for a reason: the core regulatory question — whether Beijing will allow Moomoo to continue serving mainland-adjacent users under any structure — remains unanswered.
Institutional structure is worth noting. CEO and founder Hua Li holds 36% of shares. Tencent sits at 20%. Together they control more than half the company, which means any meaningful short-covering rally or defensive buyback would have to work against a highly concentrated register. Aspex Management added over 1.2 million shares in Q1, and Capital Research and Goldman Sachs both built positions, suggesting some institutional buyers were accumulating into early-2026 weakness before the regulatory shock arrived.
Closest peer TIGR moved almost in lockstep — gaining 15% on May 26 after its own 25% crash on May 23, when it was cited alongside Futu in the CSRC action. The correlation between the two is 76%, and this week illustrated why: they share the same regulatory exposure and the same investor base. IBKR fell just 3.8% on the week and is a useful contrast — Western-regulated brokers traded the FUTU/TIGR shock as noise rather than contagion. Futu's Q2 earnings call follows tomorrow, May 28. The entire debate has now collapsed into a single question: what does management say about the CSRC fine, the timeline for resolution, and the operational impact on cross-border client acquisition.
See the live data behind this article on ORTEX.
Open FUTU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
